158 related articles for article (PubMed ID: 20391956)
41. High dose controlled-release oxycodone in hospice care.
Bercovitch M; Adunsky A
J Pain Palliat Care Pharmacother; 2006; 20(4):33-9. PubMed ID: 17182504
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodone.
Roland CL; Setnik B; Cleveland JM; Brown DA
Postgrad Med; 2011 Jul; 123(4):148-59. PubMed ID: 21680999
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets.
Koizumi W; Toma H; Watanabe K; Katayama K; Kawahara M; Matsui K; Takiuchi H; Yoshino K; Araki N; Kodama K; Kimura H; Kono I; Hasegawa H; Hatanaka K; Hiraga K; Takeda F
Jpn J Clin Oncol; 2004 Oct; 34(10):608-14. PubMed ID: 15591459
[TBL] [Abstract][Full Text] [Related]
44. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
45. Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe cancer pain.
Yu SY;
Oncology; 2008; 74 Suppl 1():46-51. PubMed ID: 18758197
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
[TBL] [Abstract][Full Text] [Related]
47. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
[TBL] [Abstract][Full Text] [Related]
48. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
[TBL] [Abstract][Full Text] [Related]
49. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain.
Friedmann N; Klutzaritz V; Webster L
Pain Med; 2011 May; 12(5):755-60. PubMed ID: 21481168
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study.
Likar R; Wittels M; Molnar M; Kager I; Ziervogel G; Sittl R
Clin Ther; 2006 Dec; 28(12):2022-39. PubMed ID: 17296459
[TBL] [Abstract][Full Text] [Related]
51. Oxycodone vs. fentanyl in the treatment of early post-operative pain after laparoscopic cholecystectomy: a randomised double-blind study.
Koch S; Ahlburg P; Spangsberg N; Brock B; Tønnesen E; Nikolajsen L
Acta Anaesthesiol Scand; 2008 Jul; 52(6):845-50. PubMed ID: 18477082
[TBL] [Abstract][Full Text] [Related]
52. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain.
Lange B; Kuperwasser B; Okamoto A; Steup A; Häufel T; Ashworth J; Etropolski M
Adv Ther; 2010 Jun; 27(6):381-99. PubMed ID: 20556560
[TBL] [Abstract][Full Text] [Related]
54. Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol.
Samolsky Dekel BG; Tomasi M; Vasarri A; Gori A; Adversi M; Castagnoli A; Di Nino G; Melotti RM
J Opioid Manag; 2014; 10(1):29-38. PubMed ID: 24604567
[TBL] [Abstract][Full Text] [Related]
55. Noninterventional observational study using high-dose controlled-release oxycodone (CR oxycodone) for cancer pain management in outpatient clinics.
Baek SK; Shin HW; Choi YJ; Zang DY; Cho DY; Ryoo HM; Baek JH; Kim SY; Song HS
Pain Med; 2013 Dec; 14(12):1866-72. PubMed ID: 24010556
[TBL] [Abstract][Full Text] [Related]
56. The use of high doses of oxycodone in an acute palliative care unit.
Mercadante S; Ferrera P; David F; Casuccio A
Am J Hosp Palliat Care; 2011 Jun; 28(4):242-4. PubMed ID: 20826490
[TBL] [Abstract][Full Text] [Related]
57. Oxycodone in the long-term treatment of chronic pain related to scleroderma skin ulcers.
Giuggioli D; Manfredi A; Colaci M; Ferri C
Pain Med; 2010 Oct; 11(10):1500-3. PubMed ID: 20456083
[TBL] [Abstract][Full Text] [Related]
58. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain.
Pan H; Zhang Z; Zhang Y; Xu N; Lu L; Dou C; Guo Y; Wu S; Yue J; Wu D; Dai Y
Clin Drug Investig; 2007; 27(4):259-67. PubMed ID: 17358098
[TBL] [Abstract][Full Text] [Related]
60. Adherence and long-term effect of oxycodone/paracetamol in chronic noncancer pain: a retrospective study.
Gatti A; Mammucari M; Sabato E; Masucci L; Sabato AF
Adv Ther; 2011 May; 28(5):418-26. PubMed ID: 21491171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
